Evidence-Based Cannabis Education · Peer-Reviewed Sources · Compliance-Forward
Policy developments, clinical research findings, market intelligence, and international updates — reported with the same evidence standards we apply to everything on this platform.
A new systematic review published in The Lancet Neurology pooling data from 1,842 patients across 14 randomized controlled trials found a 39% median reduction in monthly convulsive seizures with pharmaceutical-grade CBD versus placebo.
May 5, 2026
ReadSix months into Phase 2 of Germany's Cannabis Act, licensed social clubs are operating across 12 of 16 federal states. Early membership data, compliance rates, and what the commercial sales framework under review could mean for Europe's largest economy.
May 4, 2026
Read12 articles
After 43,000+ public comments, the DEA's proposal to move cannabis from Schedule I to Schedule III is now in final rule review. We break down what rescheduling would — and would not — change for every stakeholder group.
May 6, 2026
ReadA new systematic review published in The Lancet Neurology pooling data from 1,842 patients across 14 randomized controlled trials found a 39% median reduction in monthly convulsive seizures with pharmaceutical-grade CBD versus placebo.
May 5, 2026
ReadSix months into Phase 2 of Germany's Cannabis Act, licensed social clubs are operating across 12 of 16 federal states. Early membership data, compliance rates, and what the commercial sales framework under review could mean for Europe's largest economy.
May 4, 2026
ReadOhio's adult-use cannabis market generated $180 million in its first full retail quarter, surpassing early benchmarks set by Colorado and Michigan. The state board has approved dispensary license expansion to meet demand.
May 3, 2026
ReadA 340-patient randomized controlled trial published in Neuropsychopharmacology found significant GAD-7 score reductions at 12 weeks with CBD 300mg/day versus placebo (58% vs. 38% response rate). Researchers call for Phase III trials with active comparators.
May 2, 2026
ReadThe SAFER Banking Act, which would allow cannabis businesses to access traditional banking services, has passed the U.S. Senate for the third consecutive Congress. Industry advocates say House leadership remains the primary obstacle.
May 1, 2026
ReadThe European Commission has released its long-awaited framework classifying CBD as a novel food ingredient, giving member states 18 months to align national regulations. The decision ends years of regulatory uncertainty for the European CBD market.
Apr 30, 2026
ReadA preclinical study in Neuropharmacology found cannabigerol (CBG) significantly reduced dopaminergic neuron loss and neuroinflammatory markers in an MPTP-induced Parkinson's model. Researchers emphasize that mouse model results frequently fail to translate to human outcomes.
Apr 28, 2026
ReadMinnesota's adult-use cannabis retail launch in March 2026 drew massive consumer demand but exposed supply chain bottlenecks and licensing delays. An analysis of the state's rollout compared to other recent market openings.
Apr 25, 2026
ReadDispensary staff can be valuable guides to product selection, but there are clear limits to what they're trained and licensed to advise on. A practical guide to getting the most from dispensary consultations while knowing when to consult a clinician.
Apr 23, 2026
ReadThe Department of Veterans Affairs has updated its policy to allow VA researchers to study cannabis for PTSD treatment in veterans, reversing a longstanding prohibition. Advocates call it a landmark shift; researchers say it will take years to yield clinical guidance.
Apr 21, 2026
ReadA new analysis by independent watchdog organizations found that approximately 12.5% of cannabis products purchased from licensed dispensaries across five states had THC content deviating more than 20% from label claims. What consumers and regulators should know.
Apr 18, 2026
ReadAll news and analysis on this platform is reviewed for factual accuracy against primary sources. We cite peer-reviewed research, official government documents, and named expert sources. Opinion is clearly labeled.
We link directly to primary sources — journal articles, legislative text, regulatory filings, and official data. We do not accept sponsored content or allow advertiser influence over editorial decisions.
Factual errors are corrected promptly and transparently. Corrections are noted at the top of the affected article with the date and nature of the change. We do not silently edit published content.
